H. Lundbeck A/S - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'H. Lundbeck A/S - Product Pipeline Review - 2014', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of H. Lundbeck A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of H. Lundbeck A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of H. Lundbeck A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the H. Lundbeck A/S's pipeline products

Reasons to buy

- Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of H. Lundbeck A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the H. Lundbeck A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of H. Lundbeck A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of H. Lundbeck A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of H. Lundbeck A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
H. Lundbeck A/S Snapshot 6
H. Lundbeck A/S Overview 6
Key Information 6
Key Facts 6
H. Lundbeck A/S - Research and Development Overview 7
Key Therapeutic Areas 7
H. Lundbeck A/S - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
H. Lundbeck A/S - Pipeline Products Glance 16
H. Lundbeck A/S - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
H. Lundbeck A/S - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
H. Lundbeck A/S - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
H. Lundbeck A/S - Drug Profiles 22
carbamazepine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
vortioxetine hydrobromide 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
desmoteplase 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
LuAE-58054 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LuAF-11167 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tedatioxetine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
KW-6356 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LUAF-20513 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LUAF-64280 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Phosphodiesterase 10A Inhibitors 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
H. Lundbeck A/S - Pipeline Analysis 37
H. Lundbeck A/S - Pipeline Products by Target 37
H. Lundbeck A/S - Pipeline Products by Route of Administration 39
H. Lundbeck A/S - Pipeline Products by Molecule Type 40
H. Lundbeck A/S - Pipeline Products by Mechanism of Action 41
H. Lundbeck A/S - Recent Pipeline Updates 43
H. Lundbeck A/S - Dormant Projects 49
H. Lundbeck A/S - Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
gaboxadol 50
LuAA-47070 50
Lu-02750 50
Lu-35138 51
Lu-AA24493 51
LuAA-37096 51
LuAA-38466 51
LuAA-39959 51
LuAA-44608 52
LuAE-04621 52
LuAE-58054 52
ORE-10002 52
siramesine 52
H. Lundbeck A/S - Company Statement 53
H. Lundbeck A/S - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
H. Lundbeck A/S, Key Information 6
H. Lundbeck A/S, Key Facts 6
H. Lundbeck A/S - Pipeline by Indication, 2014 9
H. Lundbeck A/S - Pipeline by Stage of Development, 2014 10
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2014 11
H. Lundbeck A/S - Partnered Products in Pipeline, 2014 12
H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2014 13
H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2014 14
H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
H. Lundbeck A/S - Pre-Registration, 2014 16
H. Lundbeck A/S - Phase III, 2014 17
H. Lundbeck A/S - Phase II, 2014 18
H. Lundbeck A/S - Phase I, 2014 19
H. Lundbeck A/S - Preclinical, 2014 20
H. Lundbeck A/S - Discovery, 2014 21
H. Lundbeck A/S - Pipeline by Target, 2014 38
H. Lundbeck A/S - Pipeline by Route of Administration, 2014 39
H. Lundbeck A/S - Pipeline by Molecule Type, 2014 40
H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2014 42
H. Lundbeck A/S - Recent Pipeline Updates, 2014 43
H. Lundbeck A/S - Dormant Developmental Projects,2014 49
H. Lundbeck A/S - Discontinued Pipeline Products, 2014 50
H. Lundbeck A/S, Subsidiaries 55